Company Profile
Industry:Biotechnology
Site:bluebirdbio.com
Description:Exciting news (see attached Press Release), as Pregenen has been acquired by bluebird bio, Inc. (Nasdaq: BLUE), a public gene therapy company based in the Boston area.
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1943834&highlight=
Pregenen designs and engineers molecules critical to a new generation of cell-based therapies for unmet medical needs.
We work with our partners to apply our tools, services and reagents to increase the reliability,...
Specialties:gene therapy, cell-based therapeutics, homing endonucleases, cancer therapeutics, infectious disease therapeutics, genome engineering, custom enzyme engineering
Company size:1-10 employees
Summary
The organization Pregenen operates in Biotechnology field. A registered office address is 454 N 34 St, Seattle, WA 98103. For more details, please visit the official website.
Who has worked at Pregenen
| Position at Pregenen | Previous job position | |
|---|---|---|
| Jordan Jarjour | Director, Research & DevelopmentSince 2010 |
University of WashingtonGraduate Student Sep 2005 - Sep 2010 |
| Kyle Havens | ScientistSince Jun 2013 |
University of WashingtonPostdoctoral Research Associate Jan 2011 - Jun 2013 |
Former Employees
| Position at Pregenen | Next job position | |
|---|---|---|
| Andy Scharenberg | Co-founder and Member, Board of Directors2009 - 2012 |
Cellectis therapeuticsChief Scientific Officer Since Jul 2011 |
| Brett Kaiser | Principal ScientistFeb 2012 - Aug 2012 |
Seattle UniversityAssistant Professor Since Sep 2012 |
| Tomer Hertz | Bioinformatics consultantJan 2012 - Dec 2012 |
Fred Hutchinson Cancer Research CenterStaff Scientist Since Feb 2009 |